Flagship Pioneering announced on Monday, November 16, the creation of the Flagship Origination Lab, U.K., in London — its first dedicated company-creation unit outside the United States. The lab will conceive, test, fund and build AI-native platform companies focused on human and planetary health and other frontiers of science and technology.
The company has committed an initial £100 million and expects to scale that through partnerships to attract a further £500 million. The lab will operate inside Flagship Labs, the company's innovation foundry, and Flagship expects to recruit and train an initial team of around 50 scientist-entrepreneurs and operators in the UK.
Who Flagship is
Over more than 25 years, Flagship Pioneering has created more than 130 companies, including Moderna, and manages $14 billion in assets — a figure from its latest capital raise, announced in July 2024. Its current ecosystem comprises more than 40 companies, including Generate:Biomedicines, Inari, Lila Sciences, Moderna, Repertoire Immune Medicines, Tessera Therapeutics and Valo Health.
The Flagship Labs model is to conceive, fund, build and own breakthrough science and create the companies that bring it to the world: examples cited by the company itself include mRNA as medicines, the microbiome as a therapeutic, gene editing for agriculture, generative AI for biotherapeutic design and scientific superintelligence.
The relationship with the UK
The new lab builds on three years of partnerships and R&D in the country: Flagship opened a London office and signed a memorandum of understanding with the UK Government in 2023, launched its first transatlantic company, Quotient Therapeutics, and accelerated clinical trials in the UK with group companies such as Generate:Biomedicines.
Flagship founder and CEO Noubar Afeyan said the announcement “marks the beginning of a new chapter” in the company's relationship with the UK, and that the long-term commitment will complement and amplify the country's strengths. Flagship Labs president Avak Kahvejian said the UK was “a clear and deliberate choice” for the first expansion, citing its science base, clinical-trial infrastructure, genomics and health-data assets and agile regulatory environment. UK Minister for Science, Innovation and Investment Chris McDonald said the commitment will “kickstart the companies of the future” in the UK.
Image credit: David Iliff (Diliff), CC BY-SA 3.0, via Wikimedia Commons — panorama of the City of London from London City Hall.
Fontes
- Flagship Pioneering — Flagship Pioneering Launches Flagship Origination Lab in London (16/11/2026)
- PR Newswire UK — Flagship Pioneering Launches Flagship Origination Lab in London (16/11/2026)
- Unite.AI — Flagship Pioneering Launches London Lab to Build AI-Native Companies (16/11/2026)
This article was produced with the assistance of artificial intelligence, based on public posts and internet sources, and reviewed editorially. Consult the original sources for more details.
By Muse